Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (May 2018)
18 slides from Genetic Signatures's investor presentation, May 2018
Slide 1: Investor Presentation May 2018
ASX: GSS INVESTOR PRESENTATION MAY 2018 Genetic Signatures Limited Investor Presentation – May 2018
Slide 2: GSS snapshot
GSS snapshot GENETIC SIGNATURES DEVELOPS AND MANUFACTURES MOLECULAR DIAGNOSTICS KITS BASED ON ITS PROPRIETARY 3BASETM TECHNOLOGY Established Strong portfolio revenues growth Track record of Substantial product revenues de-risks growth with 5 development and products expected sales expansion by end o
Slide 3: The science behind 3base technology
The science behind 3baseTM technology THE 3BASETM TECHNOLOGY WAS PIONEERED BY GSS FOUNDERS IT GREATLY REDUCES COMPLEXITY IN GENETIC TESTING ALLOWS TESTING FOR MORE DISEASES WITH HIGHER ACCURACY 3baseTM technology 3baseTM technology in the detection process ― 3baseTM platform technology converts orig
Slide 4: EasyScreen products built on 3base technology
EasyScreenTM products built on 3baseTM technology GSS is commercialising a range of MDx tests based on 3baseTM and branded as EasyScreenTM EasyScreenTM kits offer faster and more effective detection of infectious disease 9 Four product families available 9 Common Workflow – all tests work under cove
Slide 5: Significant operational progress since IPO in 2015
Significant operational progress since IPO in 2015 Corporate Apr-15 Nov-15 Jun-16 Mar-17 First installation of Collaboration Launch ASR Launch and first 3baseTM respiratory with UCLA products in the sales of STI virus kits announced USA Genital Pathogen Aug-15 Detection Kit Mar-15 Distribution Sep-1
Slide 6: Strategy for 2018
Strategy for 2018 GENETIC SIGNATURES HAS A CLEAR FOCUS ON REVENUE GROWTH IN 2018 DRIVEN BY ITS INTERNATIONAL EXPANSION AND NEW PRODUCT RELEASES Roll-out of ― Current expectations of 5 product groups to be expanded approved in the near term across target regions product suite ― Continued progress wit
Slide 7: 3Q FY18 trading update
3Q FY18 trading update STRONG REVENUE GROWTH CONTINUES WITH SOME SEASONALITY 3Q FY18 Revenue Update Quarterly revenue (A$000) 9 Strong quarterly revenue 754 714 of A$714k in 3Q FY18, 677 +55% representing a +55% on pcp increase on pcp 575 540 9 Repeat orders of 495 Flavivirus/Alphavirus 463 460 442
Slide 8: Clear path to global commercialisation for all products
Clear path to global commercialisation for all products Australia EU US Product Trials Pilot stage Registration Ready for Registration Ready for FDA trials Clearance Products development underway revenue2 and sales trials and sales ASR trials initiated and sales Existing EasyScreen™ 2018 2019 produc
Slide 9: US$1.2bn market opportunity for existing products
US$1.2bn market opportunity for 3 existing products ENTERIC RESPIRATORY STI Commercialisation underway with Significant growth opportunity Innovative STI detection kit testing full regulatory registration in with Registrations in Australia pathogens contracted by 1 million Europe received and Europe
Slide 10: Executing a global strategy for commercialisation
Executing a global strategy for commercialisation 12+ TRIALS PLANNED GLOBALLY INCLUDING 3 DOMESTIC TRIALS 2 Europe: Rapidly increasing footprint to be ready for product approvals Trials underway 9 Increasing direct sales and support staff 9 Distributors appointed (Italy, Israel, Ireland and Poland)
Slide 11: Board of Directors have a track record of success
Board of Directors have a track record of success Anthony Radford Non executive Director • Significant sales experience • Co-Founder and CEO of Cellestis until acquired by Qiagen for c.A$400m • Proven track record of executing a sales strategy into Europe Phillip Isaacs Non executive director Michae
Slide 12: Australia: continued rapid growth
1 Australia: continue rapid growth AUSTRALIA IS THE PLATFORM FOR INTERNATIONAL SALES Commercialisation progress Next steps Established foothold Rapid customer acquisitions ― Recent relocation to larger facilities to ― Targeting trials with large hospitals and clinical accelerate next phase of operat
Slide 13: Europe: strong progress on multiple fronts
2 Europe: strong progress on multiple fronts ACTIVELY INCREASING FOOTPRINT TO BE READY FOR PRODUCT APPROVALS Commercialisation progress Next steps Distributors hired and testing underway Strategic market with large opportunity ― Currently adding to European team ― Europe has an addressable MDx marke
Slide 14: North America: accelerate direct sales approach
3 North America: accelerate direct sales approach SALES STRATEGY TO ACCELERATE FOLLOWING FDA CLEARANCE Commercialisation progress Next steps Increasing traction with ASR approach Largest market for MDx globally ― First ASR sales contract received with US ― Addressable market of approximately patholo
Slide 15: Near term focus on product range and sales growth
Near terms focus on product range and sales growth ― Commercial release of ESBL & CPO kits PRODUCTS domestically New releases ― Regulatory registrations for respiratory and STI kits AU Sales ― Strong focus of securing new customers New customers ― Additional hospital and pathology lab customers ― Ta
Slide 16: Corporate summary
Corporate summary REVENUE STAGE HEALTHCARE COMPANY LISTED ON THE ASX Genetic Signatures Limited (ASX: GSS) Share price (Ac) Volume (m) A specialist molecular diagnostics company 50 0.5 ― Focused on becoming a global leader in the 40 0.4 supply of molecular diagnostic solutions ― Developing and comme
Slide 17: Investment highlights
Investment highlights A REVENUE-STAGE HEALTHCARE COMPANY ACCELERATING THE GLOBAL COMMERCIALISATION OF ITS UNIQUE DIAGNOSTIC PRODUCTS ― Genetic Signatures (GSS) designs and manufactures Molecular Diagnostic products that have substantially greater efficacy than traditional solutions ― Domestic custom
Slide 18: Disclaimer
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Genetic Signatures — Investor Presentation (May 2018) on 6ix